From the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, the Center for Family Planning Research, Magee-Womens Research Institute, Pittsburgh, Pennsylvania; CONRAD, Eastern Virginia Medical School, Arlington, Virginia; the Department of Obstetrics and Gynecology, University Hospitals/MacDonald Women's Hospital, Case Western Reserve School of Medicine, Cleveland, Ohio; and the University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Supported by an anonymous foundation and by funds received from the NCRR CTSA Grant 1 UL1 RR024153.
Poster presentation at Reproductive Health 2009, September 30–October 3, 2009, Los Angeles, CA.
Corresponding author: Beatrice A. Chen, MD, MPH, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213; e-mail: [email protected].
Financial Disclosure Dr. Chen was a local principal investigator for a multicenter contraceptive patch study and a multicenter levonorgestrel IUD study funded by Bayer Pharmaceuticals and a local principal investigator for Medicines 360, a multicenter levonorgestrel IUD study sponsored by a nonprofit pharmaceutical organization. Dr. Reeves received an honorarium as a speaker for one event in Fall 2007 from Bayer Pharmaceuticals; payment to Dr. Reeves was directly from Bayer. Dr. Hayes received funding from Bayer Pharmaceuticals; she was previously the local principal investigator for a multicenter levonorgestrel IUD study and a local coinvestigator for a multicenter contraceptive patch study. Dr. Hohmann was a local coinvestigator for a multicenter contraceptive patch study and a multicenter levonorgestrel IUD study, and was a local coinvestigator for a multicenter levonorgestrel IUD study (Medicines 360) sponsored by a nonprofit pharmaceutical organization. Dr. Perriera was a local principal investigator for a multicenter levonorgestrel IUD study (Medicines 360) sponsored by a nonprofit pharmaceutical organization. Dr. Creinin is on the advisory board of Watson; payment to Dr. Creinin was directly from Watson. He is on the advisory board of Merck; payment to Dr. Creinin is directly from Merck. He was senior clinical advisor of a nonprofit (501c3) pharmaceutical company studying a lower-cost IUD for the U.S. and international markets (Medicines 360). Dr. Creinin's time is supported by a grant to the Magee-Womens Research Institute and received salary support. He receives royalties for a book he coedited titled Management of Unintended and Abnormal Pregnancy from Blackwell Publishing; payment to Dr. Creinin is directly from Blackwell Publishing. He is a local coinvestigator for a multicenter contraceptive patch study and a multicenter levonorgestrel IUD study and received funding from Bayer Pharmaceuticals.
